NDATRANSDERMALSYSTEM
Approved
Oct 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CATAPRES-TTS-3 (clonidine transdermal system) by Lavipharm is adrenergic alpha2-agonists [moa]. Approved for central alpha-2 adrenergic agonist [epc]. First approved in 1984.
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CATAPRES-TTS-3 is a transdermal clonidine system approved in 1984 that delivers the central alpha-2 adrenergic agonist clonidine through the skin for management of hypertension. It works by stimulating alpha-2 adrenergic receptors in the brain to reduce sympathetic outflow and lower blood pressure. The TTS-3 formulation represents the highest-dose patch in the CATAPRES-TTS family.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating contracting team focus and defensive positioning rather than growth investment.
Mechanism of Action
Adrenergic alpha2-Agonists
Pharmacologic Class:
Central alpha-2 Adrenergic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and an LOE-approaching lifecycle, working on CATAPRES-TTS-3 offers limited growth trajectory but valuable experience in defensive brand management, pricing strategy, and market transition planning. Professionals on this product will develop expertise in managing product lifecycles through patent expiration and generic competition—critical skills for pharma careers.
Brand Manager
Worked on CATAPRES-TTS-3 at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.